The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Brightline-2: brigimadlin as a 2L treatment for advanced cancers with MDM2 amplification and wtTP53
Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, Korea, provides an overview of the rationale and design of the ongoing Phase IIa/IIb Brightline-2 trial, which explores brigimadlin as a second-line treatment for advanced/metastatic cancers with MDM2 amplification and wild-type TP53, including biliary tract cancer (BTC), pancreatic ductal adenocarcinoma (PDAC), lung adenocarcinoma, and bladder cancer. As a potent MDM2-p53 antagonist, brigimadlin aims to disrupt the MDM2-p53 interaction, potentially restoring p53 function and offering a therapeutic strategy for tumors with limited treatment options and unfavorable patient outcomes in these malignancies. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
